ISFIYA, Israel, May 11, 2022 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the initiation of its U.S. pivotal trial of C-Scan® at Mayo Clinic in Rochester Minnesota.
Previous ArticleGI Research Foundation honors David T. Rubin, MD, with the prestigious Joseph B. Kirsner Award (Daily Herald)
Next Article AGAF applications now open (MDedge)
Keep Reading
Add A Comment